Return to Clinical Trials Search Results

A phase III, randomized, open-label, blinded endpoint, comparative trial of ferric derisomaltose versus no intravenous iron in irondeficient subjects with symptomatic chronic heart failure (ICONIC-HF)

Primary efficacy objective: To compare the efficacy of ferric derisomaltose to no IV iron on cardiovascular mortality and hospitalizations for worsening heart failure in irondeficient subjects with symptomatic CHF Key secondary efficacy objective: To compare the efficacy of ferric derisomaltose to no IV iron on cardiovascular mortality, all-cause mortality, hospitalizations for worsening heart failure, and all-cause hospitalizations in irondeficient subjects with symptomatic CHF